Ozempic linked to lower Alzheimer's risk in people with Type 2 diabetes

UC expert comments on study to NBC News

The University of Cincinnati's Alberto Espay, MD, commented to NBC News on new research published Oct. 24 that found semaglutide, the active ingredient in Ozempic and Wegovy, appeared to reduce the risk of Alzheimer’s disease in people with Type 2 diabetes.

The new study compared semaglutide to seven other diabetes drugs, including metformin, insulin and older GLP-1 drugs, including liraglutide. 

Researchers found that patients prescribed semaglutide had a significantly lower risk for Alzheimer’s disease than those who had taken one of the seven other diabetes drugs. The results were consistent across gender, age and weight. 

Espay, who was not involved in the study, told NBC News more research is needed to determine if the drugs actually work against Alzheimer's. He noted previous early research showed similar positive effects for people who took drugs including statins or insulin, but none of those potential treatments panned out.

“Just as with statins, NSAIDs and insulin, we should be cautious about claiming semaglutide can treat or prevent Alzheimer’s based on this study alone,” Espay said. 

Read the NBC News story.

Featured photo at top of a semaglutide injection pen. Photo/aprott/iStock.

Related Stories

1

New study links gut makeup to celiac disease development

February 25, 2026

Specific genetic architecture in the gut microbial ecosystem can shape microbial composition in ways that are potentially relevant to the pathogenesis of celiac disease, according to a study published this month in Nature Genetics.

2

Companies see up to 700% return on political investments

February 25, 2026

Accounting professor Adam Olson recently published a study in the journal of Accounting, Organizations and Society called, “The effect of political connections on COVID-19 stimulus.” Using the COVID-19 stimulus checks as reference, his team looked at how much benefit companies got if they donated to certain PACs. This dataset was a new opportunity to measure direct impact, as usually benefits from donations take the form of tax breaks or new laws down the road, not a direct deposit of cash.